Pharmaust Limited (ECQ0) Stock Price & Analysis
ECQ0 Stock Chart & Stats
- Day’s Range
- EUR 0.05 - EUR 0.05
- 52-Week Range
- EUR 0.02 - EUR 0.07
- Previous Close
- EUR 0.05
- Volume
- 0
- Average Volume (3M)
- 433
- Market Cap
- EUR 42.71M
- Enterprise Value
- EUR 36.12M
- Total Cash (Recent Filing)
- EUR 12.71M
- Total Debt (Recent Filing)
- EUR 3.31M
- Price to Earnings (P/E)
- ―
- Beta
- 0.41
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improved Capitalization
The sharp increase in equity provides a materially larger capital cushion than the prior year and may improve resilience while the company develops its business. Although losses remain significant, stronger capitalization can support operations and reduce immediate balance-sheet pressure.
Narrower Annual Loss
A reduced net loss indicates some improvement in the earnings trajectory, even though profitability remains far away. If maintained, narrowing losses could slow capital consumption, extend financial runway, and create a more credible path toward eventual operating leverage.
Reduced Cash Burn
The smaller year-on-year cash burn is a constructive change because it suggests pressure on liquidity eased somewhat in 2026. Sustaining this direction would reduce the pace of external funding needs, although absolute cash outflows remain materially negative.
Bears Say
No Recent Revenue
Revenue remaining at zero for three consecutive years indicates that the company has not yet established a recurring commercial base. Without sales generation, operating costs cannot be funded by customers, leaving future progress dependent on financing or successful commercialization.
Persistent Unprofitability
Large continuing losses and frequently negative gross profit point to a business model that has not yet demonstrated sustainable economics. This weak profitability limits internal reinvestment capacity and makes any future growth more costly to finance until margins improve.
Heavy Cash Burn And Funding Dependence
Persistent operating cash outflows, combined with renewed borrowing, indicate ongoing reliance on external funding to maintain activity. This constrains financial flexibility and exposes the company to greater financing pressure while revenue and profitability remain undeveloped.
Pharmaust Limited News
ECQ0 FAQ
What was Pharmaust Limited’s price range in the past 12 months?
What is Pharmaust Limited’s market cap?
When is Pharmaust Limited’s upcoming earnings report date?
How were Pharmaust Limited’s earnings last quarter?
Is Pharmaust Limited overvalued?
Does Pharmaust Limited pay dividends?
What is Pharmaust Limited’s EPS estimate?
How many shares outstanding does Pharmaust Limited have?
What happened to Pharmaust Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pharmaust Limited?
What is the TipRanks Smart Score and how is it calculated?
Pharmaust Limited Stock Smart Score
Company Description
Pharmaust Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chris Bremer
- Employees
- 36
- Website
- www.neurizon.com
- Address
- 385 Bourke Street, Melbourne, VIC, 3000, AU
Pharmaust Limited (ECQ0) Earnings & Revenues
ECQ0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 5 |
| Technical Analysis | 1 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |







